Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114726 | 0.93 | LMNA (0.48) | LMNAMEN1KMT2ACDK1KDR | |
| SCHEMBL2113363 | 0.92 | LMNA (0.47) | LMNAMEN1KMT2ACDK1KDR | |
| SCHEMBL2115650 | 0.91 | IGF1R (0.46) | TAAR1CDK1KDRINSRALK | |
| SCHEMBL2113337 | 0.87 | TNK2 (0.44) | TAAR1CDK1KDRINSRALK | |
| SCHEMBL5535331 | 0.84 | LMNA (0.46) | LMNAMEN1KMT2AINSRALK | |
| SCHEMBL2113595 | 0.84 | IGF1R (0.44) | KDRTNK2IGF1R | |
| SCHEMBL2113295 | 0.83 | IGF1R (0.43) | TNK2IGF1R | |
| SCHEMBL2113990 | 0.82 | HTT (0.44) | LMNAINSRALKTNK2 | |
| SCHEMBL2114996 | 0.82 | HTT (0.49) | LMNAINSRALK | |
| SCHEMBL2116827 | 0.81 | KDR (0.44) | CDK1KDRINSRALKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158641-B2 | 2-anilino-4-aminoalkyleneaminopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | LMNA 975/4885TAAR1 3765/4885MEN1 4847/4885 |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | LMNA 975/4885TAAR1 3765/4885MEN1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.